Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03674242
Title Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 1st Line Treatment of TNBC (TRYbeCA-2)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors ERYtech Pharma
Indications
Therapies
Age Groups: senior | adult
Covered Countries HUN | ESP | BEL


No variant requirements are available.